Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP-HB-IPV + pneumococcal polysaccharide
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
This is a combination immunization regimen consisting of two vaccines: - **DTaP-HB-IPV** (also known as DTaP-HepB-IPV): A combination vaccine that protects against six diseases—diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio), and *Haemophilus influenzae* type b. The mechanism of action involves stimulating the immune system to produce antibodies against the respective bacterial toxins and viral antigens[4][5]. - **pneumococcal polysaccharide** (commonly PPSV23 or PNEUMOVAX 23): A vaccine containing purified capsular polysaccharides from 23 serotypes of *Streptococcus pneumoniae*. It induces a T-cell independent immune response by promoting antibody production against these serotypes to prevent invasive pneumococcal disease[7][8]. The primary indication for this regimen is active immunization in children and adults to protect against the above diseases. The developers/manufacturers include Sanofi/Merck Sharp & Dohme for Vaxelis and Merck Sharp & Dohme for PNEUMOVAX 23.
- Brand names
- VaxelisPNEUMOVAX 23PNEUMOVAX23PNEUMOVAX-23
- Other names
- DTaP-HepB-IPV + PPSV23diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus vaccine + pneumococcal polysaccharide vaccineDTaP-HepB-IPV + Pneumovax 23
02
Targets
FHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)PRNP (Cellular Prion Protein)HBsAg (Hepatitis B surface antigen)PRN (Pertactin)CPS (Streptococcus pneumoniae capsular polysaccharide)TT (Tetanus toxoid)Diphtheria toxin
Beyond the preview
Go deeper on DTaP-HB-IPV + pneumococcal polysaccharide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP-HB-IPV + pneumococcal polysaccharide.